Neuroscientific Biopharmaceuticals Ltd
NeuroScientific Biopharmaceuticals Limited is an Australia-based company, which is engaged in developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand.
The business
NeuroScientific Biopharmaceuticals Limited is an Australia-based company, which is engaged in developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The Company's product portfolio includes EmtinB, a therapeutic peptide initially targeting glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn and EmtinBn). EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury. Its StemSmart is a global patented technology engaged in manufacturing cell products. The use of its proprietary StemSmart technology in a special access program for fistulising Crohn’s disease.
Small Caps Research
No research on Neuroscientific Biopharmaceuticals Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise NSB based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
NeuroScientific Biopharmaceuticals Reports Positive Results from StemSmart Crohn’s Trial
NeuroScientific reports on StemSmart Crohn’s trial: 80% clinical response in five patients; safe, paving Phase 2 and a potential entry to a US$13.8B market.
NeuroScientific Biopharmaceuticals Reports Strong Results from Stem Cell Study on Fistulising Crohn's Disease
NeuroScientific Biopharmaceuticals (ASX: NSB) has confirmed that 75% of patients in the first cohort of a study into its StemSmart therapy to treat fistulising Crohn’s disease have demonstrated a positive clinical response following treatment.
NeuroScientific Biopharmaceuticals Investigates Use of Stem Cell Technology on Chronic Diseases
NeuroScientific Biopharmaceuticals (ASX: NSB) is investigating the use of its newly-acquired StemSmart stem cell technology for complex indications including refractory Crohn’s disease and steroid-refractory GVHD (graft-versus-host disease). The company recently finalised the acquisition of Isopogen WA, which developed the patented technology for the manufacture of mesenchymal stromal cells (MSC), which are derived from adult human […]
NeuroScientific Biopharmaceuticals acquires Isopogen to advance stem cell therapy for neurodegenerative disorders
NeuroScientific Biopharmaceuticals (ASX: NSB) has announced it will acquire private company Isopogen WA and its StemSmart patented stem cell technology for the manufacture of mesenchymal stromal cells (MSC). The company will incorporate the cellular technology into a special access program involving the use of allogeneic bone marrow-derived MSC to treat neurodegenerative conditions where sustained healing […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.